In sickle cell the constraint is not finding patients. It is that a large, diagnosed population eligible for treatment is not receiving any.
Unlike most rare diseases, sickle cell has no meaningful diagnosis gap in developed markets - newborn screening is near-universal. The commercial question is therefore the treatment-eligible-but-untreated pool rather than an identification funnel, and that is a different analysis with different levers: access, adherence, specialist capacity and trust, rather than testing rates.
The payer case runs through Medicaid, because that is where the population sits. Patients concentrate in Medicaid-heavy states, which makes state-level policy and the federal access model for cell and gene therapies the decisive access variables. A commercial plan built around commercial payers will be aimed at the wrong buyer.
Gene therapy has to be modelled as a one-time treatment drawing from a fixed severe pool that depletes as it is treated. Revenue is front-loaded and finite, and the eligible population is a fraction of the diagnosed one, defined by disease severity rather than by genotype alone. Capacity is a further constraint: the number of qualified treatment centres, not demand, governs how fast the pool can be worked through.
Health equity belongs inside the value and access case as a commercial variable rather than as a corporate-responsibility line. The disease concentrates in Black and African American communities, and in a Medicaid-dominant payer mix access disparities translate directly into forecast risk.
AXLRx sickle cell reports size the eligible-but-untreated pool and model gene-therapy commercial life against centre capacity.
SCD epidemiology, genotype mix, VOC and organ-damage burden, and the 22-year life-expectancy gap across the US in-market population.
Gene-therapy access at $2.2–3.1M, the CMS Cell & Gene Therapy Access Model, VOC-freedom endpoints, and the hydroxyurea step-edit.
Two Dec-2023 gene therapies (Casgevy, Lyfgenia) reset a ~100,000-patient market, while voxelotor's 2024 withdrawal thins the oral field.
Two withdrawals opened a 55,000–65,000-patient white space in Sickle Cell Disease — speed, not differentiation, is the binding constraint.
GCC carries one of the highest per-capita SCD burdens globally: ~140,000 patients in Saudi Arabia alone. Both novel disease-modifiers hit regulatory trouble in 2023-2024, leaving a 25-year-old generic as the only agent with a stable market position.
Crizanlizumab's EMA/MHRA withdrawal leaves a VOC-prevention gap. Casgevy's NICE recommendation is the watershed NHS gene-therapy access event — Lyfgenia has no UK regulatory status.
Newborn screening has been universal since 1999, so the UK's 15,000-17,000 diagnosed sickle cell patients are counted with confidence. They narrow to a 4,000-6,000-patient conventional-therapy gap and a separate 200-300-per-year gene-therapy-eligible pool.
The GCC's largest rare-disease programme by patient volume sits in a commercial vacuum. Crizanlizumab and voxelotor are both withdrawn, leaving 8,000-10,000 NPHC-managed SCD patients ahead of 2025-26 gene therapy registration.
GCC SCD is the region's largest rare-disease market at 200,000-250,000 patients, with no novel SFDA-registered therapy. Post-withdrawal, the binding constraint is price, not competition or diagnosis.
Four London teaching hospitals anchor roughly 6,000 of the UK's 15,000-17,000 sickle cell patients. Barts, King's, Imperial and Homerton, with Birmingham Heartlands, Manchester, Bristol and Nottingham forming the next ring. That eight-centre structure is exactly the institutional signal this workbook sizes before any individual name enters it.
NICE's SCD gene therapy appraisal may be the largest NHS rare disease budget event in history. It hinges on an annuity payment model that current NHS SCD management cost cannot yet clearly justify.
Casgevy and Lyfgenia list at $2.2M and $3.1M, but the sticker price is not what gets paid. CMS's Cell and Gene Therapy Access Model, Medicaid concentration, and a $1.5-1.9M ICER ceiling decide the realised net.
NICE recommended crizanlizumab in 2021, then withdrew the guidance in 2023 when the confirmatory trial failed. The licence was revoked. In UK sickle cell, price is not the binding constraint. Confirmatory evidence is.
Near-universal newborn screening puts the UK's 15,000-17,000 SCD patients on the registry with confidence. But only the 4,000-6,000 hydroxycarbamide-inadequate subset is the addressable population for a new non-gene agent.
The UK has Europe's largest SCD population at 15,000–17,000 patients. Newborn screening has made diagnosis near-universal since 1999, and NICE's recommendation of Casgevy (TA1044) will define UK access to a functional cure.
Premarital screening impact, the adult transition care gap, and the gene therapy access horizon across one of the world's highest per-capita SCD burdens.
200,000-250,000 GCC sickle cell patients, with 140,000-200,000 in Saudi Arabia alone. NPHC's actively-managed registry reaches only 8,000-10,000 — the addressable near-term funnel stage within a much larger under-managed population, not a contradiction.
NICE recommended crizanlizumab (TA743) via managed access in 2021, then withdrew it in 2023 after the confirmatory trial failed. Casgevy (TA1044) cleared only by restructuring its £1.65M price into managed access. A new entrant inherits no reusable ICER benchmark from either.
NICE's rejection of crizanlizumab on price alone is the binding constraint for any new SCD agent. 4,000-6,000 UK patients sit in a post-withdrawal white space, and the WAC ceiling decides whether you repeat that outcome.
Only three GCC institutions run structured adult sickle cell programmes for 200,000-250,000 patients. KFSH&RC, KAMC and AUH. That three-centre concentration, anchored by the KFSH&RC Dammam flagship and 12+ MOH regional centres in Eastern Province, is exactly the institutional signal this workbook sizes before any individual name enters it.
An estimated 100,000 US sickle cell patients narrow to a 55,000-65,000-patient pool with no adequate novel therapy. Only 50-100 of the gene-therapy-eligible minority were actually treated in year one.
At 200,000-250,000 GCC patients, US or UK list pricing is commercially impossible. NPHC's own exceptional-access threshold caps a novel agent near SAR 8,000-20,000/year, a fraction of a $2.2M gene-therapy WAC.
A ~100,000-patient US SCD population narrows to a 55,000-65,000-patient addressable white space. Only 50-100 gene-therapy patients were actually treated in the first 12 months, versus 200-300 projected.
Carrier-rate-adjusted epidemiology implies 140,000-200,000 KSA sickle cell patients. NPHC's structured active-management programme reaches only 8,000-10,000 — a care-registration gap, not a measurement error.
About 100,000 Americans live with sickle cell disease (SCD), occurring in roughly 1 in 365 Black or African American births. Genotypes span HbSS (60-65%, the most severe phenotype), HbSC (~25%), and HbS/beta-thalassemia. Unlike most rare diseases, SCD is almost universally identified, US newborn screening catches nearly every case at birth. The commercial gap is not finding patients; it is treating them. That inversion defines every sizing and access question in SCD.
Diagnosis happens at birth, but the funnel narrows sharply afterward, at treatment and specialist access. Hydroxyurea, the disease-modifying backbone, reaches only 25-30% of eligible patients despite more than 25 years of availability. Gene therapy requires referral to a qualified treatment center, months of myeloablative conditioning and apheresis, and center throughput that caps annual capacity. Adult transition care remains a persistent weak point. The rate-limiting step in SCD is access, not identification.
Two one-time gene therapies were FDA-approved in December 2023 for patients aged 12 and older: Casgevy (exagamglogene autotemcel, Vertex/CRISPR Therapeutics), a CRISPR-Cas9 edit priced near $2.2M, and Lyfgenia (lovotibeglogene autotemcel, bluebird bio), a lentiviral therapy priced near $3.1M that carries a boxed warning for hematologic malignancy. The disease-modifying backbone is generic hydroxyurea, L-glutamine (Endari, Emmaus Life Sciences), and crizanlizumab (Adakveo, Novartis). Voxelotor (Oxbryta, Pfizer) was withdrawn in 2024.
Not from a diagnosis funnel. In SCD the patients are already found through newborn screening, so the defensible number is the treatment-eligible-but-untreated pool. Build it bottom-up: about 100,000 diagnosed, then the estimated 20,000-30,000 with severe recurrent vaso-occlusive disease relevant for gene therapy, then the fraction reachable given specialist-access and treatment-center capacity limits. The variable that moves the number most is hydroxyurea underuse (only 25-30% of eligible patients are treated) and referral gaps, not undiagnosed prevalence. Any SCD forecast built on prevalence alone overstates the near-term pool; the access funnel, not the epidemiology, is the strategy.
Not as a recurring-revenue curve. A one-time cure at $2.2-3.1M draws from a fixed severe pool of roughly 20,000-30,000 patients that depletes as it is treated, so revenue is front-loaded and finite. Build an eligible-pool depletion curve, then cap annual uptake by qualified-treatment-center throughput, since myeloablative conditioning and apheresis capacity, not demand, set the ceiling. Layer outcomes-based contract cashflow, where payment ties to durable vaso-occlusive-crisis freedom rather than a single lump sum, and adjust the reachable pool for equity and access gaps. The output is a bounded, capacity-gated annuity, not a perpetual franchise.
Around Medicaid, because that is where SCD sits. The US population concentrates in Medicaid-heavy Southern states, so the payer case runs through CMS's Cell and Gene Therapy Access Model, launched in 2024, which lets states enter outcomes-based contracts tying manufacturer payment to durable vaso-occlusive-crisis freedom, enabled by a best-price rebate waiver. Model the cashflow as milestone-linked rather than upfront, and factor the universal hydroxyurea step-edit (a documented six-month trial at maximum tolerated dose before authorization) which adds months given the 25-30% baseline utilization. State budget capacity, not clinical eligibility alone, gates the timing of every case.
Because it is not a soft add-on here; it is a core commercial variable. SCD is concentrated in Black and African American communities and, in a Medicaid-dominant payer mix, access disparities directly shape the reachable pool. The 25-30% hydroxyurea gap, uneven specialist and treatment-center distribution, and long-standing under-investment mean an equity-adjusted access layer is what separates the eligible population from the actually-treatable one. A value case that models a whole-population benefit without that layer overstates uptake and misreads the real barrier. In SCD the equity dimension is the access funnel, quantified.
The analysis behind the questions above: a bottom-up model that sizes the treatment-eligible-but-untreated pool rather than a diagnosis funnel; a one-time gene-therapy commercial-life model with eligible-pool depletion, center-capacity uptake ceilings, and outcomes-based contract cashflow; payer and access-model economics built around the CMS Cell and Gene Therapy Access Model and the hydroxyurea step-edit; competitive intelligence on the Casgevy-Lyfgenia contest and the disease-modifying backbone; and an equity-adjusted access layer throughout. Each is scoped to your asset and delivered as a sourced brief, an editable model, or an executive readout.